Navigation Links
Cohera Medical Raises Over $25 Million in Series C Round
Date:12/19/2011

PITTSBURGH, Dec. 19, 2011 /PRNewswire/ -- Cohera Medical, a leading innovator and developer of absorbable surgical adhesives and sealants, announced today that it has secured over $25 million Series C financing through private investors.  A total of $16.5 million was raised through existing investors and over $9 million was raised through new investors, which significantly bolstered the round.

The company will use the funds to expand adoption in Germany and additional European markets for its lead product, TissuGlu® Surgical Adhesive.  The funds will also be used to support the clinical trials for TissuGlu in the United States.  TissuGlu is an internal surgical adhesive for large flap surgeries, such as abdominoplasty (tummy tuck), that helps reduce fluid accumulation and the need for postsurgical drains. 

"In its first two months, TissuGlu has been used successfully in over 160 plastic surgery procedures in Germany by leading plastic and reconstructive surgeons," said John C. Kern, Founder and General Partner of Kern Whelan Capital, LLC, and Manager of Kern Medical III. "We believe that TissuGlu has the potential to fundamentally transform the patient recovery process worldwide, across many types of surgical procedures, while saving surgeons significant time and money through the reduction of post-surgical complications."

"In just five years, we have taken TissuGlu from a benchtop experiment to a commercially viable product – a significant achievement for our company," said Patrick Daly, President and CEO of Cohera Medical.  "We have reached several major milestones this year, and our ability to attract both new and existing investors is a reflection of their confidence that we can generate long-term and sustainable growth."

Cohera Medical recently received

SOURCE Cohera Medical, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Cohera Medical Commercializes TissuGlu® Surgical Adhesive in Germany
2. Cohera Medical and CEO Receive Pittsburgh Tech 50 Awards
3. Cohera Medical Receives CE Mark Approval for TissuGlu® Surgical Adhesive
4. Frost & Sullivan Recognizes Cohera Medical, Inc.® for Developing TissuGlu®, Its Pioneering Surgical Adhesive That Is Strong, Easy-To-Use, Biocompatible and Resorbable
5. First Patient Treated in Clinical Study of Cohera Medicals TissuGlu(R) Surgical Adhesive
6. Medical Alarm Concepts™ Chosen as a Strategic Alliance Partner with Costco Warehouse Clubs
7. Medical Centers Worldwide Adopt Both Accurays CyberKnife and TomoTherapy Systems
8. Sanomedics Signs Letter of Intent to Acquire East Coast Based Durable Medical Equipment Business
9. Gerresheimer Extends Production of Medical Plastic Systems in Bavaria
10. Veran Medical Technologies Launches New SPiN Drive™ Application for Bi-Planar Virtual Fluoroscopy View
11. Saladax Biomedical, Inc. Expands Distribution of My5-FU in Europe
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 15, 2014  Zafgen, Inc., a leading biopharmaceutical company ... obese patients, today announced initial results from its ... of methionine aminopeptidase 2 (MetAP2), in patients with ... obesity.  These results showed improvements in body weight, ...
(Date:1/14/2014)... Texas , Jan. 14, 2014  Luminex Corporation (Nasdaq: ... results for the fourth quarter of 2013 on Monday, February ... for release after the close of trading. ... conference call to discuss the operating highlights and financial results ...
(Date:1/14/2014)... Jan. 14, 2014 Dynamic Healthcare Services, Inc. ("DHS"), a ... it acquired Progressive Home Medical Equipment, Inc. ("Progressive") of ... terms of the acquisition were not disclosed. ... providing a wide range of sleep, mobility, and respiratory products ...
Breaking Medicine Technology:Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 3Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 2Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 3
... According to Marcia Crosse (Director, Health Care at GAO ... health has been compromised. In her comments on why oversight ... says : "The Food and Drug ... all Americans. FDA,s role is far-reaching: from over-the-counter pain relievers ...
... 19, 2012 /PRNewswire-Asia/ -- ShangPharma Corporation (NYSE: ... leading China-based pharmaceutical and biotechnology research and development ... the first milestone in its strategic partnership with ... Chinese pharmaceutical company, to develop novel therapeutic monoclonal ...
Cached Medicine Technology:Physician-Patient Alliance for Health & Safety: Can There Be Too Much FDA Oversight? 2Physician-Patient Alliance for Health & Safety: Can There Be Too Much FDA Oversight? 3Physician-Patient Alliance for Health & Safety: Can There Be Too Much FDA Oversight? 4ShangPharma Announces Milestone Achievement in Research Partnership with Hengrui 2ShangPharma Announces Milestone Achievement in Research Partnership with Hengrui 3ShangPharma Announces Milestone Achievement in Research Partnership with Hengrui 4
(Date:4/17/2014)... Queen,s University Belfast,s Vice-Chancellor, Professor Patrick Johnston, whose work ... elected as a Fellow of the European Academy of ... is an independent advisory body of highly distinguished oncologists ... and suffering caused by cancer in Europe. , Professor ... Northern Ireland move from the bottom of the UK ...
(Date:4/16/2014)... STANFORD, Calif. Consider the marvel of the embryo. It ... and function as they multiply to become the cells of ... of the body. , Now, in a feat of reverse ... complex genetic coding that allows embryonic cells to proliferate and ...
(Date:4/16/2014)... A team that includes scientists from the School of ... San Antonio, Johns Hopkins University and St. Mary,s University reported ... to infect the body. , The fungal pathogen Candida ... and is the most common fungal pathogen to infect humans. ...
(Date:4/15/2014)... the United States have nearly doubled since 1988, suggests new ... with obesity apparently to blame for the surge. The researchers ... hit all groups equally, with alarming increases in diabetes in ... reported in the April 15, 2014 issue of the ...
(Date:4/15/2014)... the RECIST Working Group published in the European Journal ... refined categorization of tumor response or various aspects of progression ... They found that modeling target lesion tumor growth did ... that of the other components of progression. The RECIST Working ...
Breaking Medicine News(10 mins):Health News:Stanford scientists develop 'playbook' for reverse engineering tissue 2Health News:Stanford scientists develop 'playbook' for reverse engineering tissue 3Health News:Pre-diabetes and diabetes nearly double over the past 2 decades 2Health News:Can refined categorization improve prediction of patient survival in RECIST 1.1? 2
... By Randy Dotinga HealthDay Reporter , WEDNESDAY, ... certain heart patients will fare about the same whether ... that uses drug-coated stents to prop open clogged arteries. ... procedures, which also require much less recovery time. However, ...
... Cincinnati (UC) and Cincinnati Children,s Hospital Medical Center ... primarily to prevent rejection in organ transplant patients, ... The Multicenter International LAM Efficacy of Sirolimus ... designed to develop a therapy for this life-threatening ...
... MD, MPH, Medical Director and Principal Investigator of IMPACT ... Children,s National Medical Center, served as the Site Principal Investigator ... outcomes, specifically for inner-city children and teens. Findings from a ... were published and released in the March 17 issue of ...
... By Steven Reinberg HealthDay Reporter , ... in the United States reached an all-time low in ... percent from 2008, federal health officials report. , "There ... a statistician at the U.S. Centers for Disease Control ...
... By Steven Reinberg HealthDay Reporter , WEDNESDAY, ... drug cytarabine work as well as the high doses that ... fewer side effects, a new Dutch study finds. Cytarabine ... along with other chemotherapy drugs and stem cell transplantation. Cytarabine ...
... It is no surprise to scientists that the largest social ... their face is fundamental to our social interactions, one of ... how our brain processes facial identity. In a ... scientists used an original approach a method that "shakes" ...
Cached Medicine News:Health News:Bypass Surgery, Stents Seem to Bring Same Level of Relief 2Health News:Bypass Surgery, Stents Seem to Bring Same Level of Relief 3Health News:New therapy found for rare lung disorder 2Health News:New therapy found for rare lung disorder 3Health News:Stephen J. Teach, MD, MPH, part of landmark study on pediatric asthma 2Health News:U.S. Death Rate at All-Time Low: CDC 2Health News:U.S. Death Rate at All-Time Low: CDC 3Health News:Less Is More With Acute Myeloid Leukemia Drug 2Health News:Innovative technique gives vision researchers insight into how people recognize faces 2
... Control of thumb motion can be ... stroke, for persons with spinal cord injuries ... due to cerebral palsy or other motor ... positions the thumb for control and coordination. ...
... stabilizes the MP joint and the CMC joint of ... of both of the thumb joints. An excellent choice ... but who need maximum mobility for daily activities. Ideal ... thumb and for those with pain due to repetitive ...
... profile contour at the palmar crease to allow ... excellent choice to treat mild to moderate wrist ... wear following cast removal. The lightweight laminated ... fasteners provides support and compression to the wrist ...
... common site for arthritis in the hand. The ... the wrist or other joints of the thumb. ... or reduce subluxation of the CMC joint of ... without pain. Also useful for persons experiencing pain ...
Medicine Products: